Skip to content

Rationalisation of Polypharmacy by the RASP-instrument and Discharge Counselling of Geriatric Inpatients

Rationalisation of Polypharmacy by the RASP-instrument (Rationalisation of Home Medication by an Adjusted STOPP-list and Discharge Counselling of Geriatric Inpatients: a Prospective, Clinical Trial

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05816967
Enrollment
0
Registered
2023-04-18
Start date
2018-10-31
Completion date
2019-09-30
Last updated
2023-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polypharmacy

Brief summary

Systematic evaluation of polypharmacy in geriatric patients, through a validated list by a clinical pharmacist. The goal is reduction of potentially inappropriate medications (PIMs). A brief counseling session with the patient and/or his/her caregiver will be part of the intervention.

Detailed description

This project is focused on the systematic evaluation of polypharmacy in older patients admitted to the acute geriatric wards of a university hospital. Polypharmacy will be identified through a validated list by a clinical pharmacist. The goal is reduction of potentially inappropriate medications (PIMs). Before hospital discharge the hospital pharmacist will have a brief counseling session with the patient and/or his/her caregiver in order to discuss the medication list and to enhance compliance.

Interventions

PROCEDUREMedication review and discharge counseling

Medication reconciliation of home therapy will be performed by the clinical pharmacist through a standardized form. Next, the clinical pharmacist will perform a medication review, based on but not limited to the RASP list (Van der Linden 2014). The goal is optimization of therapy. Before discharge the clinical pharmacist will perform a second medication review, together with the treating physician and a medication reconciliation in orde to provide the best possible discharge medication list. The medication list will be provided 3 times: once for the patient and/or his/her caregiver, once for the general practitioner and once for the primary care pharmacist. Finally the clinical pharmacist will have a counseling session with the patient and/or his/her caregiver.

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Informed consent by the patient and/or his/her caregiver * Admission through the emergency department of patients coming from home or a residential care facility

Exclusion criteria

* Patients not speaking Dutch * Patients admitted for end of life care * Patients not taking any drugs on admission

Design outcomes

Primary

MeasureTime frameDescription
Acceptance rate of the pharmacotherapeutic recommendations, provided by the clinical pharmacist by the general practitioner.1 month (30 days) after dischargeAcceptance rate of the pharmacotherapeutic recommendations, provided by the clinical pharmacist by the general practitioner.

Secondary

MeasureTime frameDescription
Number of drugs at discharge versus at admission.At discharge from the index hospitalization (as mentioned in the discharge medication scheme) vs on admission (during the first 72 hours of the index hospitalization)Number of drugs at discharge versus at admission.
Number of drugs adapted by the treating physician based on recommendations by the clinical pharmacist that are not included in the RASP list.At discharge from the index hospitalization (as mentioned in the discharge medication scheme), compared to the medication list obtained on admission (this is, during the first 72 hours of the hospitalization)Number of drugs adapted by the treating physician based on recommendations by the clinical pharmacist that are not included in the RASP list.
Difference in number of potentially inappropriate medications identified through the RASP list on admission versus at dischargeAt discharge from the index hospitalisation (as mentioned in the discharge medication scheme) versus on admission (medication list obtained in the first 72 hours) of the index hospitalizationDifference in number of potentially inappropriate medications identified through the RASP list on admission versus at discharge
Number of potentially inappropriate medications on admission, at discharge and at the follow-up moments (1 and 3 months after discharge)On admission (medication list obtained in the first 72 hours of the admission), at discharge (as mentioned in the discharge medication scheme), 1 (30 days) month after discharge, 3 months (90 days) after dischargeNumber of potentially inappropriate medications on admission, at discharge and at the follow-up moments (1 and 3 months after discharge)
Mortality during admissionDuring the index hospitalization, from admission to the emergency ward until moment of death on the geriatric ward, assessed up to 72 hours after death.Mortality during admission
Number of falls during hospitalizationDuring the index hospitalization, from admission on the emergency ward until discharge from the geriatric ward, assessed within 72 hours after discharge.Number of falls during hospitalization
Number of fractures during hospitalizationduring the index hospitalization, from admission to the emergency ward until discharge from the geriatric ward, assessed within 72 hours after discharge.Number of fractures during hospitalization
Length of stayDuring the index hospitalization, from admission to the emergency ward until discharge from the geriatric ward, assessed within 72 hours after discharge.Length of stay
Number of drug intakes at discharge versus at admission.At discharge from the index hospitalization (as mentioned in the discharge medication scheme) vs on admission (during the first 72 hours of the index hospitalization)Number of drug intakes at discharge versus at admission.
Number of fractures at 3 months after discharge3 months (90 days) after discharge from the geriatric ward (index hospitalization), assessed at day 90Number of fractures at 3 months after discharge
Number of falls 3 months after discharge3 months (90 days) after discharge from the geriatric ward (index hospitalization), assessed at day 90Number of falls 3 months after discharge
Mortality at 3 months after discharge3 months (90 days) after discharge from the geriatric ward (index hospitalization), assessed at day 90Mortality at 3 months after discharge
Category of potentially inappropriate medications identified through the RASP list on admission and at dischargeOn admission (medication list obtained in the first 72 hours of the admission), at discharge (as mentioned in the discharge medication scheme)Category of potentially inappropriate medications identified through the RASP list on admission and at discharge
Category of drugs adapted by the treating physician based on recommendations by the clinical pharmacist that are not included in the RASP list.During the course of the index hospitalization, defined as the period between discharge from the geriatric ward and admission to the geriatric department. The outcome parameter will be assessed within 72 hours of discharge.Category of drugs adapted by the treating physician based on recommendations by the clinical pharmacist that are not included in the RASP list.
Number of drugs at follow-up (1 month and 3 months after discharge)1 month (30 days) and 3 months (90 days) after the index hospitalizationNumber of drugs at follow-up (1 month and 3 months after discharge)
Number of drug intakes at follow-up (1 month and 3 months after discharge)1 month (30 days) and 3 months (90 days) after the index hospitalizationNumber of drug intakes at follow-up (1 month and 3 months after discharge)
Readmission rate 3 months after discharge3 months (90 days) after discharge from the geriatric ward (index hospitalization), assessed at day 90Readmission rate 3 months after discharge

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026